Chang Chen

Stories

AI-designed IPF drug enters Phase III trial, a first for generative AI

As of September 2026: President, Shanghai Pulmonary Hospital

Insilico Medicine dosed the first patient this week in a Phase III trial of Rentosertib, a drug for the progressive lung disease idiopathic pulmonary fibrosis. It's the first medicine with both an AI-identified target and an AI-designed molecule to reach this stage of testing.

Updated Sep 11